Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure

Novo Nordisk’s hopes of revolutionizing obesity treatment with its CagriSema drug have been cast into doubt following disappointing trial results, including lower-than-expected weight loss percentages in late-stage trials for patients with type 2 diabetes and comorbidities. These results led to a significant drop in Novo’s stock value, as investors had high expectations for CagriSema as a potential competitor to existing GLP-1 medications. The company’s shares have plummeted around 50% from their 2024 peak, reflecting a negative sentiment among investors and analysts alike.

Full Article